160727-95-7

Basic information

• Product Name: Methyl 3-chloro-3-(4-fluorophenyl)-2-oxopropanoate
• Synonyms: Methyl 3-chloro-3-(4-fluorophenyl)-2-oxopropanoate
• CAS NO: 160727-95-7
• Molecular Weight: 230.623
• Mol File: 160727-95-7.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: Methyl 3-chloro-3-(4-fluorophenyl)-2-oxopropanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 3-chloro-3-(4-fluorophenyl)-2-oxopropanoate(160727-95-7)
• EPA Substance Registry System: Methyl 3-chloro-3-(4-fluorophenyl)-2-oxopropanoate(160727-95-7)

Safety Data

• Hazardous Substances Data: 160727-95-7(Hazardous Substances Data)

Upstream product

• 116-54-1 dichloroacetic acid methyl ester 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 886361-30-4 2-amino-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester 
• 1007873-79-1 methyl 5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carboxylate 
• 1038508-94-9 2-bromo-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester 
• 1355079-11-6 5-bromo-N-(3,4-dichlorobenzyl)-N-[2-(dimethylamino)ethyl]-3-(4-fluorophenyl)imidazo[1,2-a]pyridine-2-carboxamide 
• 1355082-42-6 5-bromo-3-(4-fluorophenyl)imidazo[1,2-a]pyridine-2-carboxylic acid 
• 1355082-41-5 methyl 5-bromo-3-(4-fluorophenyl)imidazo[1,2-a]pyridine-2-carboxylate hydrochloride 
• 6091-44-7 piperidine hydrochloride 
• 1038508-87-0 2-cyclopropyl-5-(4-fluoro-phenyl)-thiazole-4-carboxylic acid methyl ester 
• 433283-22-8 5-(4-fluorophenyl)-2-methyl-1,3-thiazole-4-carboxylic acid 

Relevant articles and documents

SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS

There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

Synthetic studies of centromere-associated protein-E (CENP-E) inhibitors: 1.Exploration of fused bicyclic core scaffolds using electrostatic potential map

Centromere-associated protein-E (CENP-E), a mitotic kinesin that plays an important role in mitotic progression, is an attractive target for cancer therapeutic drugs. For the purpose of developing novel CENP-E inhibitors as cancer therapeutics, we investigated a fused bicyclic compound identified by high throughput screening, 4-oxo-4,5-dihydrothieno[3,4-c]pyridine-6-carboxamide 1a. Based on this scaffold, we designed inhibitors for efficient binding at the L5 site in CENP-E utilizing homology modeling as well as electrostatic potential map (EPM) analysis to enhance CENP-E inhibitory activity. This resulted in a new lead, 5-bromoimidazo[1,2-a]pyridine 7, which showed potent CENP-E enzyme inhibition (IC50: 50 nM) and cellular activity with accumulation of phosphorylated histone H3 in HeLa cells. Our homology model and EPM analysis proved to be useful tools for the rational design of CENP-E inhibitors.

PIPERIDINE AND PYROOLIDINE COMPOUNDS

The invention relates to piperidine and pyrrolidine compounds of formula (I) wherein A, B, n and X are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds use as medicaments, especially as orexin receptor antagonists.